Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H22N2O2.ClH |
Molecular Weight | 418.915 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC[C@H](NC(=O)C1=C(O)C(=NC2=C1C=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=BHCSUEHQURQVLD-BDQAORGHSA-N
InChI=1S/C25H22N2O2.ClH/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18;/h3-16,20,28H,2H2,1H3,(H,27,29);1H/t20-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C25H22N2O2 |
Molecular Weight | 382.4544 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://ncats.nih.gov/files/SB223412.pdfCurator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800009015
https://en.wikipedia.org/wiki/Talnetant
Sources: https://ncats.nih.gov/files/SB223412.pdf
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800009015
https://en.wikipedia.org/wiki/Talnetant
Talnetant (SB-223412) is a selective, orally active neurokinin 3 receptor antagonist and is under development for the potential treatment of several disorders, including irritable bowel syndrome, schizophrenia, chronic obstructive pulmonary disease, cough, overactive bladder and urinary incontinence. The most common adverse effects were headache, fatigue, and nausea.
CNS Activity
Sources: https://ncats.nih.gov/files/SB223412.pdf
Curator's Comment: SB223412 crosses the blood-brain barrier to a significant extent.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866 |
1.0 nM [Ki] | ||
Target ID: CHEMBL2327 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866 |
144.0 nM [Ki] | ||
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9190866 |
100.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18755817/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TALNETANT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day multiple, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, ADULT n = 275 Health Status: unhealthy Condition: schizophrenia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 275 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://ncats.nih.gov/files/SB223412.pdf
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/17727393
25 or 100 mg over 14-17 days.
0.1 mg to 1000 mg as single doses; up to 800 mg twice daily on repeat doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://ncats.nih.gov/files/SB223412.pdf
SB223412 antagonized senktide-induced contraction of rabbit isolated iris sphincter muscle (KB = 1.6 nM), and inhibited NK-3 receptorinduced
membrane depolarization in guinea-pig bronchial parasympathetic ganglia and substantia nigra pars compacta in guinea pig.
SB223412 inhibited senktide-induced miosis in rabbits when given iv (ED50 = 0.44mg/kg) and by 53% when given orally (25 mg/kg, PO).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:59:19 GMT 2023
by
admin
on
Fri Dec 15 15:59:19 GMT 2023
|
Record UNII |
C1ZIJ8F59E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL10188
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
DBSALT002012
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
C1ZIJ8F59E
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
204519-66-4
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
9844955
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
DTXSID50942628
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
KK-81
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY | |||
|
C152498
Created by
admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |